Sanofi’s Cablivi Wins China NMPA Approval – First Nanobody Drug for aTTP
Sanofi (NASDAQ: SNY) announced that its anti‑vWF Nanobody Cablivi (caplacizumab for injection) received formal marketing...
November 2025
Judge Rejects Pfizer’s Attempt to Block Novo Nordisk’s $10 bn Bid for Metsera
Delaware Court of Chancery Judge Morgan Zurn denied Pfizer’s (NYSE: PFE) request for a temporary...
Amgen Reports 12% YoY Sales Growth in Q3 2025, Raises Full‑Year Revenue Guidance
US‑based biotech giant Amgen (NASDAQ: AMGN) posted its third‑quarter 2025 results, showing total sales of...
AstraZeneca Posts 11% Y/Y Revenue Rise to $43.24 bn in First Nine‑Months of 2025
AstraZeneca (AZ, NASDAQ: AZN) released its third‑quarter and nine‑month 2025 financial results, showing total revenues...
NHSA Concludes 2025 National Basic Medical Insurance Drug Catalogue Negotiation and Commercial Insurance Innovative Drug Price Talks
The National Healthcare Security Administration (NHSA) wrapped up a week‑long series of negotiations and bidding...
XtalPi’s Ailux Strikes $345 Million Partnership with Eli Lilly to Co‑Develop Bispecific Antibodies
Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) disclosed that its wholly‑owned subsidiary Ailux...
Siemens Shanghai Gains NMPA Clearance for Prostate‑Cancer AI Detection Software
Siemens Shanghai Medical Equipment Ltd. (SSME) announced that the National Medical Products Administration (NMPA) has...
HBM’s Subsidiary Nona Biosciences Teams Up with Umoja Biopharma to Co‑Develop In‑Vivo CAR‑T Platforms
HBM Holdings Limited (HKG: 2142) announced that its wholly‑owned subsidiary Nona Biosciences (Suzhou) Co., Ltd....
Shandong Jincheng Pharma Subsidiary Jincheng Taier to Sell Proxyl Vaginal Capsule Tech & MAH Rights to Shanghai Hemony for RMB 50 M
Shandong Jincheng Pharmaceutical Group Co., Ltd. (SHE: 300233) disclosed that its wholly‑owned subsidiary Jincheng Taier...
Sinotau Receives FDA NDA Approval for MK‑6240 Tau PET Imaging Agent
Beijing Sinotau International Pharmaceutical Technology Co., Ltd. announced today that the New Drug Application (NDA) for...
Baheal Pharma Locks CSL Behring Albumin Rights to Boost China’s Blood Product Supply
Baheal Pharma Group (SHE: 301015), a prominent Chinese therapeutic manufacturer, announced an enhanced cooperation agreement...
Prelude Therapeutics Revamps Pipeline: Incyte Option on JAK2V617F, KAT6A Degrader Takes Center Stage, SMARCA2 Paused
Prelude Therapeutics (NASDAQ: PRLD) unveiled a suite of strategic shifts: it signed an option deal...
UCB Wins FDA Approval for KYGEVVI in Rare Mitochondrial Disease TK2d
UCB (EBR: UCB) announced that KYGEVVI received FDA approval for the treatment of adult and...
Dizal Highlights Breakthrough Findings for golidocitinib and birelentinib at ASH 2025
Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that multiple research updates for its two core...
Jiangsu Vcare’s VC004 Joins NMPA’s SPARK Oncology Program
The Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has officially...
Pfizer’s Q3 2025 Results: COVID‑19 Sales Slide While Eliquis Soars
US pharmaceutical heavyweight Pfizer Inc. (NYSE: PFE) posted Q3 2025 revenues of $16.7 B – a...
Jiangsu Hengrui Secures Priority Review for HRS‑5965 in China’s Rare‑Disease Portfolio
Jiangsu Hengrui Pharmaceuticals (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration (NMPA)...
Pluvicto Radioligand Therapy Receives Dual NMPA Approvals in China
Novartis (NYSE: NVS) has announced that its Lutetium‑177‑labelled therapy Pluvicto (lutetium ¹⁷⁷Lu‑vipivotide tetraxetan) now holds...
Sichuan Biokin Secures Breakthrough Therapy Designation for HER2‑Targeted ADC T‑Bren
China’s Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its proprietary antibody‑drug conjugate (ADC)...
Shenzhen Kangtai Biological Products Launches Phase I Trial for Infant Influenza Vaccine
China‑based Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) has entered the clinical stage with...